Tasimelteon (Hetlioz) for Non-24-Hour Sleep-Wake Disorder
Tasimelteon (Hetlioz) for Non-24-Hour Sleep-Wake Disorder
April 28, 2014 (Issue: 1441)
The FDA has approved the melatonin receptor agonist
tasimelteon (Hetlioz – Vanda) for treatment of non-24-hour sleep-wake disorder (non-24), which is common
in totally blind persons. Tasimelteon is the first drug
approved for this indication and...more
1. Ramelteon (Rozerem) for insomnia. Med Lett Drugs Ther 2005; 47:89.
2. Drugs for insomnia. Treat Guidel Med Lett 2012; 10:57.
3. RL Sack et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep 2007; 30:1484.
4. SA Ferguson et al. Melatonin agonists and insomnia. Expert Rev Neurother 2010; 10:305.
5. SW Lockley et al. Tasimelteon treatment entrains the circadian clock and demonstrates a clinically meaningful benefit in totally blind individuals with non-24-hour circadian rhythms. The Endocrine Society 95th annual meeting (ENDO), San Francisco, June 15-18, 2013. Poster SUN-134.
6. SW Lockley et al. RESET study demonstrates that tasimelteon maintains entrainment of melatonin and cortisol in totally blind individuals with non-24-hour circadian rhythms. The Endocrine Society 95th annual meeting (ENDO), San Francisco, June 15-18, 2013. Poster SUN-137.
7. SM Rajaratnam et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomized controlled multicentre trials. Lancet 2009; 373:482.
8. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
9. Approximate wholesale acquisition cost (WAC). Source: Analy$ource® Monthly (Selected from FDB MedKnowledge™) April 5, 2014. Reprinted with permission by FDB, Inc. All rights reserved. ©2014. www.fdbhealth. com/policies/drug-pricing-policy. Actual retail prices may be higher.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Tasimelteon (Hetlioz) for Non-24-Hour Sleep-Wake Disorder
Article code: 1441b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
